Generative AI in Pharma and Drug Discovery
Join CXOTalk Live?episode number 782?as we explore the latest developments in generative AI and drug discovery with?Alex Zhavoronkov, CEO of?Insilico?Medicine. Discover how AI is transforming the pharmaceutical industry by accelerating drug development and identifying new drug targets.
Alex Zhavoronkov, Ph.D.?is the founder and CEO of?Insilico?Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and?biomarker?development. He is also the founder of Deep Longevity, Inc, a spin-off of?Insilico?Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020, Deep Longevity was acquired by Endurance Longevity (HK: 0575). Beginning in 2015, he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for the generation of novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered applications of deep learning technologies for the prediction of human biological age using multiple data types, and transferred learning from aging into disease, target identification, and signaling pathway modeling.
Under his leadership,?Insilico?has raised over $400 million in multiple rounds from expert investors, opened R&D centers in six countries or regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions, nominated 11 preclinical candidates, and has generated positive?topline?Phase 1 data in human clinical trials with an AI-discovered novel target and AI-designed novel molecule for idiopathic pulmonary fibrosis that received Orphan Drug Designation from the FDA and is nearing Phase 2 clinical trials.?Insilico?also recently announced that its generative AI-designed drug for COVID-19 and related variants was approved for clinical trials.
Since 2012, he has published over 150 peer-reviewed research papers, and 2 books including "The Ageless Generation: How Biomedical Advances Will Transform the Global Economy" (Macmillan, 2013). He serves on the advisory or editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and founded and co-chairs the Annual Aging Research and Drug Discovery conference, the world's largest event on aging in the pharmaceutical industry. He is an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
During the live event, join us on Twitter using?#cxotalk?and ask our guest any questions. We welcome your comments!?
=========
Subscribe to the CXOTalk newsletter?to be notified of upcoming live shows.
=========
RECENT AND UPCOMING LIVE SHOW SCHEDULE
Oct. 14:?Chief Information Technology Officer, United Nations?
Oct 28:?Chief Information Officer and EVP, Storage Services, Seagate?
Nov 4:?Chief Technology Officer, Otis Elevator?
Nov 11:?Co-Founder, Digital Initiative, Harvard Business School?
Nov 18:?Chief Growth Officer, Marc Cuban Companies and Rhodes Scholar/Author
Dec 2:?Chief Digital Evangelist, Salesforce
Jan 6:?Global Chief Information Officer and CTO Solutions & Services Group, Lenovo
领英推荐
Jan 20:?TikTok AI star on AI tools
Jan 27:?Chief Security Officer and Head of Product Security, NVIDIA
Feb 3:?Chief Security Officer and Head of Product Security, Expedia Group?and?Chief Growth Officer, Mark Cuban Companies (guest co-host)
Feb 10:?Professor,?Harvard Business School and?Chief Growth Officer, Marc Cuban Companies?(guest co-host)
Feb 17:?Global CTO, EY
Mar 3:??Chief Data and Analytics Officer,?The National Football League (NFL) and?Chief Growth Officer, Mark Cuban Companies (guest co-host)
Mar 10:?Chief Technology Officer, Gen
Mar 24:?CEO,?Insilico?Medicine
Mar 31:?No show
Apr 7:?Chief Analytics Officer, Estee Lauder
Apr 14:?Head of Data and Analytics, Google Cloud
Apr 21:?No show
Apr 28:?Chief Data Officer, Goldman Sachs
May 5:?No show
May 12:?Vice Dean for Research and Chief Marketing Officer, Columbia University Business School
May 26:?No show
Jun 2:?Former President, MGM Resorts International
Jun 30:?CEO, Magna International
Co-founder and V.P. at Asuret, Inc.
2 年This should be really interesting because of the scientific application as opposed to consumer application of generative AI.
Go-to-Market Leader | AI Automation Strategist | Author | Driving Growth Through Intelligent Solutions
2 年My second favourite use case other than end-to-end automation in Ambulatory.